

Pathkind Diagnostics Private Limited
Balance Sheet as at March 31, 2020
All amounts are in INR unless otherwise stated

	Notes	As at March 31, 2020	As at March 31, 2019
Equity and liabilities			
Shareholder's funds			
Share capital	3	63,50,00,000	51,52,50,000
Reserves and surplus	4	(89,22,24,693)	(71,86,71,546)
		<u>(25,72,24,693)</u>	<u>(20,34,21,546)</u>
Non-current liabilities			
Borrowings	5	61,44,84,661	52,05,68,475
Other liabilities	6	1,30,15,020	50,95,262
Provisions	7	1,02,53,591	46,83,260
		<u>63,77,53,272</u>	<u>53,03,46,997</u>
Current liabilities			
Trade payables	8		
- total outstanding dues of micro enterprises and small enterprises		37,66,356	42,04,328
- total outstanding dues of creditors other than micro enterprises and small enterprises		6,59,87,428	6,71,58,506
		<u>6,43,05,474</u>	<u>6,69,69,695</u>
Provisions	7	71,15,672	52,80,725
		<u>14,11,74,930</u>	<u>14,36,13,254</u>
Total		<u>52,17,03,509</u>	<u>47,05,38,705</u>
Assets			
Non-current assets			
Property, Plant & Equipment			
Tangible assets	9	31,35,27,627	31,45,55,622
Intangible assets	10	1,82,59,011	2,23,98,850
Loans and advances	11	6,78,36,435	4,95,75,568
Deferred tax Assets (net)	12	28,40,164	-
Other assets	13	65,92,205	19,06,696
		<u>40,90,55,442</u>	<u>38,84,36,736</u>
Current assets			
Inventories	14	4,56,36,932	3,51,81,568
Trade receivables	15	1,65,53,141	1,04,27,769
Cash and cash equivalents	16	3,55,79,962	2,28,24,436
Loans and advances	11	1,48,78,032	1,36,68,196
		<u>11,26,48,067</u>	<u>8,21,01,969</u>
Total		<u>52,17,03,509</u>	<u>47,05,38,705</u>

The accompanying notes are an integral part of these financial statements

1-35

As per our report of even date

For Bhagi Bhardwaj Gaur & Co.
Chartered Accountants
F.R No.: 007895N

Mohit Gupta
Partner
M. No. 528337



For and on behalf of the Board of Directors

Eklavya Juneja
(Director)
DIN:-06754247

Sanjeev Vashista
(Managing Director & CEO)
DIN:-01457971

Prabhat Singh
(Company Secretary)
M. No:- FCS-8724

Place: New Delhi
Date: 08-12-2020

Place: New Delhi
Date: 08-12-2020



Pathkind Diagnostics Private Limited
Statement of profit and loss for the year ended March 31, 2020
All amounts are in INR unless otherwise stated

	Notes	Year ended March 31, 2020	Year ended March 31, 2019
(I) Revenue from operations	17	71,63,37,619	42,47,78,606
(II) Other income	18	5,73,281	-
(III) Total Income		<u>71,69,10,900</u>	<u>42,47,78,606</u>
(IV) Expenses			
Cost of reagents, chemicals, surgicals and laboratory supplies consumed	19	20,43,88,553	14,82,14,781
Employee benefit expenses	20	36,20,71,155	27,99,34,304
Depreciation and amortisation expense	21	5,69,75,601	5,07,53,811
Finance costs	22	10,55,030	6,79,526
Other expenses	23	53,76,40,812	41,21,97,738
(V) Total Expenses		<u>1,16,21,31,151</u>	<u>89,17,80,160</u>
(VI) Profit before tax (III - V)		<u>(44,52,20,251)</u>	<u>(46,70,01,554)</u>
(VII) Tax expenses:			
Current tax		-	-
Deferred tax	12	(28,40,164)	-
Total tax expense		<u>(28,40,164)</u>	<u>-</u>
(VIII) Profit for the year (VI - VII)		<u>(44,23,80,087)</u>	<u>(46,70,01,554)</u>

Earnings per equity share [nominal value of share Rs. 10 (March 31, 2018: Rs. 10)]	24		
Basic		(44.24)	(46.70)
Diluted		(44.24)	(46.70)

The accompanying notes are an integral part of these financial statements 1-35

As per our report of even date

For Bhagi Bhardwaj Gaur & Co.
Chartered Accountants
F.R No.: 007895N



Mohit Gupta
Partner
M. No. 528337



For and on behalf of the Board of Directors


Eklavya Juneja
(Director)
DIN:-06754247


Sanjeev Vashistha
(Managing Director & CEO)
DIN:-01457971


Prabhat Singh
(Company Secretary)
M. No:- FCS-8724

Place: New Delhi
Date: 08-12-2020

Place: New Delhi
Date: 08-12-2020



Pathkind Diagnostics Private Limited
Cash flow statement for the year ended March 31, 2020
All amounts are in INR unless otherwise stated

	Year ended March 31, 2020	Year ended March 31, 2019
A. Cash flow from operating activities		
Net profit before tax	(44,52,20,251)	(46,70,01,554)
Non - cash adjustments to reconcile profit before tax to net cash flows		
Depreciation / amortisation	5,69,75,601	5,07,53,811
Profit/Loss on sale/ disposal of fixed assets (net)	(52,282)	34,35,477
Provision for doubtful debts and advances	6,60,272	-
Interest expense	10,55,030	6,79,526
Interest income	(4,82,441)	-
Operating profit before working capital changes	(38,70,64,071)	(41,21,32,740)
Movements in working capital:		
(Increase)/ Decrease in trade receivables	(67,85,644)	(79,69,878)
(Increase)/Decrease in inventories	(1,04,55,364)	14,85,728
(Increase)/ Decrease in loans & advances - current	(12,09,836)	(81,77,867)
(Increase)/ Decrease in other non current assets	(2,00,000)	-
Increase/ (Decrease) in trade payables	(16,09,050)	(1,14,46,641)
Increase/ (Decrease) in provisions - current	18,34,947	(8,41,212)
Increase/ (Decrease) in provisions - non current	55,70,331	23,90,657
Increase/ (Decrease) in other non current liability	79,19,758	27,45,521
Increase/ (Decrease) in other current liability	(56,09,446)	2,63,60,491
Cash generated from operations	(39,76,08,376)	(40,75,85,941)
Direct taxes paid (net of refunds)	(44,85,509)	(17,61,244)
Net cash flow from operating activities	(40,20,93,884)	(40,93,47,185)
B. Cash flow from investing activities		
Purchase of Property Plant & Equipment (net of insurance claim received on disposal)	(5,15,03,653)	(5,68,14,764)
Loans and advances	(1,55,67,474)	(79,71,946)
Interest received	4,82,441	-
Net cash (used in) investing activities	(6,65,88,686)	(6,47,86,710)
C. Cash flow from financing activities		
Proceeds from issuance of preference share capital	23,95,00,000	24,05,00,000
Proceeds of long-term borrowings	24,29,18,000	23,00,00,000
Interest paid	(5,68,844)	(2,60,040)
Share issue expense	(4,11,060)	-
Net cash (used in) financing activities	48,14,38,096	47,02,39,960
Net (decrease) / Increase in cash and cash equivalents (A+B+C)	1,27,55,526	(38,93,935)
Cash and cash equivalents acquired pursuant to purchase of business		
Cash and cash equivalents at the beginning of the year	2,28,24,436	2,67,18,371
Cash and cash equivalents at the end of the year 16	3,55,79,962	2,28,24,436
Components of cash and cash equivalents		
Cash on hand	9,49,342	15,31,534
Balance with scheduled banks:		
-in current accounts	3,46,30,620	2,12,92,902
-on cash credit accounts	-	-
-Deposits with original maturity of less than three months	-	-
-on fixed deposit accounts	-	-
Total cash and cash equivalents (refer note 16)		
Less: Fixed deposits not considered as cash equivalents	-	-
Cash & Cash Equivalents in Cash Flow Statement: 16	3,55,79,962	2,28,24,436

The accompanying notes are an integral part of these financial statements 1-35

For Bhagi Bhardwaj Gaur & Co.

Chartered Accountants

F.R. No. 1007896N

Mohit Gupta
Partner
M. No. 528387



For and on behalf of the Board of Directors

Eklavya Juneja
(Director)
DIN:-06754247

Sanjeev Vashista
(Managing Director & CEO)
DIN:-01457971

Prabhat Singh
(Company Secretary)
M. No:- FCS-8724

Place: New Delhi
Date: 08-12-2020

Place: New Delhi
Date: 08-12-2020



Pathkind Diagnostics Private Limited

Notes to financial statements for the year ending March 31, 2020

Note 1: Background

Pathkind Diagnostics Private limited was incorporated on 6th October 2016 to engage in the business of running laboratories for carrying out pathological investigations of various branches of Bio-chemistry, Haematology, Histopathology, Microbiology, Electrophoresis, Immuno-Mistry, Immunology, Cytology, other pathological and radiological investigations.

Note 2: Significant Accounting Policies

2.1 Statement of Compliance

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in India (Indian GAAP). The Company has prepared these financial statements to comply in all material respects with the notified under Section 133 of the Companies Act, 2013, read together with paragraph 7 of the Companies (accounts) Rules, 2014.

2.2 Basis of Preparation

The financial statements have been prepared on an accrual basis and going concern under the historical cost convention.

These financial statements are presented in Indian Rupce (INR), which is the functional currency of the country.

2.3 Revenue Recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. The following specific recognition criteria is also met before revenue is recognized:

i) Pathology services

-Laboratory Income

Revenue comprises of amount gross billed in respect of tests conducted and is recognized at and when the samples are registered for the purpose of conducting the tests.

-Revenue from Collection Centers

Till March 31, 2019, the Company recognized the revenue from Collection Centers as the amount billed (net of Service Charge) in respect of tests conducted when the samples are registered for the purpose of conducting the tests.

With effect from April 01, 2019, The Company has recognized the revenue from the Collection Centers at the gross amount charged to the Collection Centers in respect of tests conducted when the samples are registered for the purpose of conducting the tests.

However, this policy change has no impact on the profitability of the Company.

ii) Sale of goods

Sales are considered, net of returns and trade discounts, on transfer of significant risks and rewards of ownership to the buyer, which generally coincides with the delivery of goods to customers.

iii) Income from other services

Revenues from other services are recognized when services are rendered and related costs are incurred.



2.4 Accounting of reagent rental equipments

The Company has entered into agreements with certain suppliers for purchase of reagent. As part of the agreement, the Company has the right to use equipment supplied by the suppliers free of charge subject to purchase of minimum committed quantities of reagents. The cost of reagents which includes the cost of rental of the equipment is recorded as cost of material consumed.

2.5 Lease

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee. All other leases are classified as operating leases.

Where the Company is lessee

Leases, where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item, are classified as operating leases. Operating lease payments are recognized as an expense in the statement of profit and loss on a straight-line basis over the lease term.

2.6 Retirement and other employee Benefits

Retirement benefit in the form of provident fund is a defined contribution scheme. The contributions to the provident fund are charged to the statement of profit and loss for the year when the contributions are due.

The Company operates a defined benefit plans for its employees, viz., gratuity. The costs of providing benefits under this plan is determined on the basis of actuarial valuation at each year-end. Actuarial valuation is carried out for plan using the projected unit credit method. Actuarial gains and losses for defined benefit plan is recognized in full in the period in which they occur in the statement of profit and loss.

Accumulated leave, which is expected to be utilized within the next 12 months, is treated as short-term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

2.7 Taxation

Income tax expenses comprises current tax (i.e. the amount of the tax for the period determined in accordance with the income-tax Law) and deferred tax charge or credit (reflecting the tax effects of timing difference between accounting income & taxable income for the period). Income tax liability is ascertained on the basis of profit computed in accordance with the provisions of Income-Tax Act, 1961.

Deferred tax charge or credit reflect the tax effects of timing difference between accounting income & taxable income for the period. The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognized using the rates that have been enacted or substantively enacted by the Balance Sheet date. Deferred tax assets are recognized only to the extent there is a reasonable certainty that the assets can be realized in future. However, in case there is an unabsorbed depreciation or carried forward loss under taxation law, deferred tax assets are recognized only if there is virtual certainty of realization of such assets. Deferred tax assets are reviewed as at each Balance Sheet date and written down or written-up to reflect the amount that is reasonably/virtually (as case may be) to be realized. Deferred Tax Assets on unused tax losses are recognized only to the extent of net Deferred tax liabilities.



2.8 Property, Plant & Equipment

(i) Tangible Assets

Fixed assets are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. The cost comprises purchase price, borrowing costs if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Any trade discounts and rebates are deducted in arriving at the purchase price.

Subsequent expenditure related to an item of fixed asset is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance. All other expenses on existing fixed assets, including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the statement of profit and loss for the period during which such expenses are incurred. Fixed Assets under construction, advance paid towards the acquisition of fixed assets and cost of assets not put to use if any before the year end are disclosed as Capital Work-in-Progress.

(ii) Intangible Assets

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired at purchase of business is recorded at their fair value as at the date of purchase of business. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any. Internally generated intangible assets, excluding capitalized development costs, are not capitalized and expenditure is reflected in the statement of profit and loss in the year in which the expenditure is incurred.

(iii) Depreciation

- I. Leasehold Improvements are depreciated over the useful life of the assets or the unexpired lease period, whichever is lower.
- II. Depreciation on all other fixed assets is provided using the Straight Line Method at the rates computed based on the estimated useful life of all assets as prescribed under the Schedule II of the Companies act, 2013 and estimated by the management.

The Company has considered following useful lives to provide depreciation on fixed assets:

Tangible Assets	Useful Life (in years)
Leasehold Improvements	6 – 9
Plant & Machinery	13
Office Equipments	5
Other Equipments	3
Computers / Servers	3 / 5
Furnitures & Fixtures	10
Vehicles – Cars	8
Low Value Assets	1

- III. Intangible assets are amortized using the straight line method over their useful lives as under:

Intangible Assets	Useful Life (in years)
Computer Software	4



2.9 Borrowing Costs

Borrowing cost includes interest, amortization of ancillary costs incurred in connection with arrangement of borrowings.

Borrowing costs directly attributable to the acquisition, construction or production of an assets that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective assets. All other borrowing costs are expensed in the period they occur.

2.10 Impairment

The Carrying Value of the assets are reviewed at each Balance sheet date to determine whether there is any indication of Impairment. If any, such indication exists, the recoverable amount of the assets is estimated. For assets that are not available for use, the recoverable amount is estimated at each Balance Sheet date. The recoverable is the highest of net selling price and its value in use. An Impairment loss is recognized whenever the carrying amount of an assets or its cash generating unit exceeds its recoverable amount. Impairment losses are recognized in the Profit & loss account. An Impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An Impairment loss is reversed only to the extent that the carrying amount of assets does not exceed the carrying amount that would have been determined net of depreciation or amortization, if no impairment loss had been recognized.

2.11 Inventories

Inventories comprise of reagents, chemicals, surgical and laboratory supplies and stores and others are valued at lower of cost and net realizable value. Cost is determined on moving weighted average basis.

2.12 Provisions

A provision is recognized when the Company has a present obligation as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

2.13 Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably.

2.14 Cash and cash equivalents (for purpose of Cash Flow Statement)

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.



(i) Cash flow statement

Cash flows are reported using the indirect method, whereby profit before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

2.15 Foreign Exchange Transaction

Foreign currency transactions and balances

(i) Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

(ii) Conversion

Foreign currency monetary items are retranslated using the exchange rate prevailing at the reporting date. Non-monetary items, which are measured in terms of historical cost denominated in a foreign currency, are reported using the exchange rate at the date of the transaction. Non-monetary items, which are measured at fair value or other similar valuation denominated in a foreign currency, are translated using the exchange rate at the date when such value was determined.

(iii) Exchange Differences

Exchange differences arising on the settlement of monetary items or on reporting Company's monetary items at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognized as income or as expenses in the year in which they arise.

2.16 Earnings Per Share

Basic earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) as adjusted for dividend, interest and other charges to expense or income (net of any attributable taxes) relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share from continuing ordinary operations. Potential dilutive equity shares are deemed to be converted as at the beginning of the period, unless they have been issued at a later date. Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for share splits / reverse share splits and bonus shares, as appropriate.

2.17 Segment reporting policy

The Company prepares its segment information in conformity with the accounting policies adopted for preparing and presenting the financial statements of the Company as a whole.



Pathkind Diagnostics Private Limited
Notes to financial statements for the year ending March 31, 2020

2.18 Operating cycle

The Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

2.19 Use of estimates

The preparation of financial statements in conformity with Indian GAAP which requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.



Pathkind Diagnostics Private Limited

Notes to financial statements for the year ended March 31, 2020

All amounts are in INR unless otherwise stated

3. Share capital	March 31, 2020	March 31, 2019
Authorised		
1,00,00,000 equity shares of Rs. 10 each (Previous year 1,00,00,000 equity shares of Rs. 10 each)	10,00,00,000	10,00,00,000
5,35,00,000 Preference share of Rs. 10 each (Previous year 5,20,00,000 Preference share of Rs. 10 each)	53,50,00,000	52,00,00,000
	63,50,00,000	62,00,00,000
Issued, subscribed & fully paid-up		
1,00,00,000 equity shares of Rs. 10 each (Previous year 1,00,00,000 equity shares of Rs. 10 each)	10,00,00,000	10,00,00,000
5,35,00,000 Preference share of Rs. 10 each (Previous year 4,15,25,000 Preference share of Rs. 10 each)	53,50,00,000	41,52,50,000
	63,50,00,000	51,52,50,000

Notes :

(a) Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting year

<i>Equity shares</i>	March 31, 2020		March 31, 2019	
	No. of shares	Amount	No. of shares	Amount
At the beginning of the year	1,00,00,000	10,00,00,000	1,00,00,000	10,00,00,000
Issued during the year	-	-	-	-
Outstanding at the end of the year	1,00,00,000	10,00,00,000	1,00,00,000	10,00,00,000

Preference shares

	March 31, 2020		March 31, 2019	
	No. of shares	Amount	No. of shares	Amount
At the beginning of the year	4,15,25,000	41,52,50,000	2,20,00,000	22,00,00,000
Issued during the year (refer note e below)	1,19,75,000	11,97,50,000	1,95,25,000	19,52,50,000
Outstanding at the end of the year	5,35,00,000	53,50,00,000	4,15,25,000	41,52,50,000

(b) Terms/ rights attached to equity shares

The Company has only one class of equity shares having par value of Rs. 10 per share. Each member holding equity shares therein shall have voting rights in proportion to the member's share of the paid up equity share capital. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the equity shareholders.

(c) Terms/ rights attached to preference shares

The Company has two class of preference shares having par value of Rs. 10 per share carrying a coupon rate of 0.1% per annum. The Company has issued 25,00,000 Optionally Convertible Preference Shares and 5,10,00,000 Compulsory Convertible Preference Shares as approved by the Shareholders in their respective meetings. The OCPS are redeemable/convertible and CCPS are only convertible into equity shares as per terms and conditions mentioned in the Securities Subscription Agreement dated 18th January, 2017. The CCPS shall always carry preference to any dividend and/ or distribution payable on equity shares and any other class of preference shares (including optionally convertible preference shares) but only after payment of interest on debentures. Preference shares shall not participate in the surplus funds, surplus assets and surplus profits on winding up, which may remain after entire capital has been repaid.



Pathkind Diagnostics Private Limited

Notes to financial statements for the year ended March 31, 2020

All amounts are in INR unless otherwise stated

(d) Detail of shareholders holding more than 5% shares in the Company

Name of the shareholder	March 31, 2020		March 31, 2019	
	No. of shares	% holding	No. of shares	% holding
Equity shares of Rs. 10/- each fully paid				
Mr. Arjun Juneja	35,02,200	35.02%	35,02,200	35.02%
Mr. Rajeev Juneja	29,63,400	29.63%	29,63,400	29.63%
Mr. Sheetal Arora	25,14,400	25.14%	25,14,400	25.14%
Mr. Sanjeev Vashishta	10,00,000	10.00%	10,00,000	10.00%
	99,80,000	99.80%	99,80,000	99.80%
Optionally Convertible, non-participating preference shares of Rs. 10/- each fully paid				
Beyondtime Consultants Private Limited	25,00,000	4.67%	25,00,000	6.02%
	25,00,000	4.67%	25,00,000	6.02%
Compulsory Convertible, non-participating preference shares of Rs. 10/- each fully paid				
Mr. Arjun Juneja	87,50,000	16.36%	57,56,250	13.86%
Mr. Rajeev Juneja	2,79,70,000	52.28%	2,23,41,750	53.80%
Mr. Sheetal Arora	1,42,80,000	26.69%	1,09,27,000	26.31%
	5,10,00,000	95.33%	3,90,25,000	93.98%

As per records of the Company, including its register of shareholders/ members and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownerships of shares.

(e) During the year, Company has issued 1,19,75,000 Compulsory Convertible Preference Shares (CCPS) having face value of Rs.10 each on preferential allotment basis. Compulsory Convertible Preference Shares (CCPS) having face value of Rs.10 each were issued at a premium of Rs.10/- each.



Pathkind Diagnostics Private Limited
Notes to financial statements for the year ended March 31, 2020
All amounts are in INR unless otherwise stated

4. Reserves and surplus	March 31, 2020	March 31, 2019
Securities premium account		
Balance at the beginning of the year	4,52,50,000	-
Addition on issue of Preference Shares (refer note 3(e))	11,97,50,000	4,52,50,000
Addition on issue of Debentures-(refer note 5(c))	14,94,88,000	
Less: Preference shares issue expenses	4,11,060	
Balance at the end of year	31,40,76,940	4,52,50,000
Surplus in the statement of profit and loss		
Balance as per the last financial statements	(76,39,21,546)	(29,69,19,992)
Profit/(loss) for the year	(44,23,80,087)	(46,70,01,554)
Net surplus in the statement of profit and loss	(1,20,63,01,633)	(76,39,21,546)
	(89,22,24,693)	(71,86,71,546)

5. Borrowings	March 31, 2020	March 31, 2019
Non Current		
Unsecured Borrowings from related parties		
0.1% Optionally Convertible Debentures (25,00,000 debenture of Rs 10 each, Previous year 25,00,000 debenture of Rs 10 each)	2,50,70,061	2,50,47,500
0.1% Compulsory Convertible Debentures (5,88,43,000debenture of Rs 10 each, Previous year 4,95,00,000 debenture of Rs 10 each)	58,94,14,600	49,55,20,975
	61,44,84,661	52,05,68,475

Notes:

(a) Borrowings from Optionally Convertible Debentures includes interest accrued of INR 70,061/- as at March 31, 2020 and INR 47,500/- as at March 31, 2019.

(b) Borrowings from Compulsory Convertible Debentures includes interest accrued of INR 9,84,600/- as at March 31, 2020 and INR 5,20,975/- as at March 31, 2019.

(c) During the year, Company has issued 93,43,000 0.1% Compulsory Convertible Debentures having face value of Rs.10 each at a premium of Rs.16/- each.

6. Other Liabilities	March 31, 2020	March 31, 2019
Non Current		
Lease equalisation reserve	1,30,15,020	50,95,262
	1,30,15,020	50,95,262
Current		
Payable for Property, Plant & Equipment	69,30,827	39,85,601
Trade deposits	1,01,75,000	61,84,000
Advances from customers	3,75,19,996	4,35,59,858
Statutory dues payable	96,79,651	1,32,40,236
	6,43,05,474	6,69,69,695

7. Provisions	March 31, 2020	March 31, 2019
Non Current		
Provision for employee benefits		
Provision for gratuity (refer note 25)	1,02,53,591	46,83,260
	1,02,53,591	46,83,260
Current		
Provision for employee benefits		
Provision for leave encashment	71,15,672	52,80,725
	71,15,672	52,80,725

8. Trade Payables	March 31, 2020	March 31, 2019
Current		
- total outstanding dues of micro and small enterprises (refer note no. 29)	37,66,356	42,04,328
- total outstanding dues of creditors other than micro and small enterprises	6,59,87,428	6,71,58,506
	6,97,53,784	7,13,62,834



Pathkind Diagnostics Private Limited
Notes to financial statements for the year ended March 31, 2020
All amounts are in INR unless otherwise stated

10. Intangible Assets	March 31, 2020	March 31, 2019
Computer Software	1,82,59,011	2,23,98,850
	1,82,59,011	2,23,98,850
Particulars	Computer Software	Computer Software
Gross block		
As at 01.04.2017		-
Additions	3,04,52,231	3,04,52,231
Deletions		
As at 31.03.2018	3,04,52,231	3,04,52,231
Additions	85,52,176	85,52,176
As at 31.03.2019	3,90,04,407	3,90,04,407
Additions	45,13,265	-
As at 31.03.2020	4,35,17,672	3,90,04,407
Accumulated Amortization		
As at 01.04.2017		-
Depreciation for the year	86,42,201	86,42,201
As at 31.03.2018	86,42,201	86,42,201
Depreciation for the year	79,63,356	79,63,356
As at 31.03.2019	1,66,05,557	1,66,05,557
Depreciation for the year	86,53,104	
As at 31.03.2020	2,52,58,661	1,66,05,557
Net block		
As at 31.03.2018	2,18,10,030	2,18,10,030
As at 31.03.2019	2,23,98,850	2,23,98,850
As at 31.03.2020	1,82,59,011	



Pathkind Diagnostics Private Limited
Notes to financial statements for the year ended March 31, 2020
All amounts are in INR unless otherwise stated

11. Loans and advances	March 31, 2020	March 31, 2019
Non Current		
Capital advances	47,84,895	20,91,502
Trade / security deposits	1,77,41,879	1,74,46,566
Loan and advances to related parties (refer note 31)	3,00,00,000	3,00,00,000
Loans and advances to Others	1,53,09,661	37,500
Total	6,78,36,435	4,95,75,568
Current		
Advance to suppliers	60,86,496	20,46,989
Advances to employees	36,51,290	31,07,522
Prepaid expenses	40,25,493	34,45,184
Balances with government authorities	11,14,753	50,06,001
Loans and advances to Others	-	62,500
Total	1,48,78,032	1,36,68,196



Pathkind Diagnostics Private Limited
Notes to financial statements for the year ended March 31, 2020

All amounts are in INR unless otherwise stated

	March 31, 2020	March 31, 2019	
12. Deferred Tax Liabilities (net)			
Deferred tax balances			
Deferred tax liabilities	52,15,672	55,86,164	
Deferred tax assets	80,55,836	55,86,164	
Deferred tax liabilities (net)	(28,40,164)	-	
Year ended 31 March 2020	Opening Balance	Recognised In Profit or loss	Closing balance
Deferred tax liabilities in relation to			
Property, plant and equipment	55,86,164	(3,70,493)	52,15,672
	55,86,164	(3,70,493)	52,15,672
Deferred tax assets in relation to			
Provision for employee benefits	30,75,256	14,40,753	45,16,008
Unclaimed Preliminary expenses	2,33,883	(77,961)	1,55,922
Unused tax losses	11,88,036	(11,88,036)	-
Lease equalisation reserve	10,19,302	23,64,603	33,83,905
Others	69,687	(69,687)	-
	55,86,164	24,69,672	80,55,836
Deferred tax liabilities (net)	-	(28,40,164)	(28,40,164)
Year ended 31 March 2019	Opening Balance	Recognised In Profit or loss	Closing balance
Deferred tax liabilities in relation to			
Property, plant and equipment	42,15,980	13,70,184	55,86,164
	42,15,980	13,70,184	55,86,164
Deferred tax assets in relation to			
Provision for employee benefits	22,15,617	8,59,639	30,75,256
Unclaimed Preliminary expenses	3,11,844	(77,961)	2,33,883
Unused tax losses	13,52,603	(1,64,567)	11,88,036
Lease equalisation reserve	3,05,466	7,13,836	10,19,302
Others	30,450	39,238	69,687
	42,15,980	13,70,184	55,86,164
Deferred tax liabilities (net)	-	-	-

Deferred tax assets and liabilities are being offset as they relate to taxes on income levied by the same governing taxation laws.



Pathkind Diagnostics Private Limited
Notes to financial statements for the year ended March 31, 2020
All amounts are in INR unless otherwise stated

13. Other assets	March 31, 2020	March 31, 2019
Non Current		
Income tax (net of provision)	63,92,205	19,06,696
Deposits with banks (original maturity more than one year)	2,00,000	-
Total	65,92,205	19,06,696
14. Inventories		
March 31, 2020		
March 31, 2019		
In hand		
Reagents, chemicals, surgicals and laboratory supplies	4,56,36,932	3,51,81,568
	4,56,36,932	3,51,81,568
15. Trade receivables		
March 31, 2020		
March 31, 2019		
Unsecured, considered good unless stated otherwise		
Outstanding for a period exceeding six months from the date they are due for payment	-	-
Outstanding for a period less than six months from the date they are due for payment	1,72,13,413	1,04,27,769
Provision for Bad Debts	(6,60,272)	-
Total	1,65,53,141	1,04,27,769
16. Cash and bank balances		
March 31, 2020		
March 31, 2019		
Cash and cash equivalents		
Balance with banks in current accounts	46,07,684	2,12,92,902
Cash in hand	9,49,342	15,31,534
Deposits with bank (original maturity less than 3 months) (see note 1 below)	3,00,22,936	-
	3,55,79,962	2,28,24,436

Note:

1. It include interest accrued amounting to INR 22,936 as at March 31, 2020



Pathkind Diagnostics Private Limited

Notes to financial statements for the year ended March 31, 2020

All amounts are in INR unless otherwise stated

	March 31, 2020	March 31, 2019
17. Revenue from operations		
Sale of pathology services	69,77,66,756	40,83,62,758
Other operating Revenue	1,85,70,863	1,64,15,848
Revenue from operations (net)	71,63,37,619	42,47,78,606
18. Other income		
Interest Income on Bank Deposits	4,82,441	-
Net gain on sale of Property Plant & Equipment	52,282	-
Net gain on foreign exchange fluctuation	38,558	-
	5,73,281	-
19. Cost of reagents, chemicals, surgicals and laboratory supplies consumed		
Inventories at the beginning of the year	3,51,81,568	3,66,67,296
Add : Purchases during the year	21,48,43,917	14,67,29,053
	25,00,25,485	18,33,96,349
Less : Inventories at the end of the year	4,56,36,932	3,51,81,568
Cost of reagents, chemicals, surgicals and laboratory supplies consumed	20,43,88,553	14,82,14,781
20. Employee benefits expenses		
Salaries, wages and bonus	33,33,61,498	25,78,90,931
Contribution to provident and other funds	1,50,54,562	1,22,11,087
Gratuity expense (refer note 25)	55,70,331	23,90,657
Staff welfare expenses	80,84,764	74,41,629
	36,20,71,155	27,99,34,304
21. Depreciation and amortisation expense		
Depreciation of tangible assets	4,83,22,497	4,27,90,455
Amortisation of intangible assets	86,53,104	79,63,356
	5,69,75,601	5,07,53,811
22. Finance costs		
Interest expense on:		
- borrowings	5,40,207	4,66,095
- Interest expense on delayed deposit of statutory dues	5,14,823	2,13,431
	10,55,030	6,79,526



Pathkind Diagnostics Private Limited

Notes to financial statements for the year ended March 31, 2020

All amounts are in INR unless otherwise stated

23. Other expenses	March 31, 2020	March 31, 2019
Electricity and water charges	1,62,79,887	1,50,41,151
Rent	5,90,72,133	4,79,99,026
Rates and taxes	33,52,629	44,47,530
Insurance	17,89,648	11,66,362
Repairs and maintenance		
- Building	23,22,020	15,86,232
- Plant and machinery	29,09,354	6,54,524
- Others	83,84,859	47,17,384
Advertisement and sales promotion	4,71,44,798	6,37,07,490
Travelling and conveyance	4,05,12,613	3,40,61,054
Vehicle running and maintenance	71,721	1,12,049
Postage and courier	5,22,15,337	4,04,57,662
Communication cost	55,08,232	54,92,163
Retainership Fess to technical consultant's	1,60,91,068	92,03,122
Printing and stationary	82,50,342	71,74,202
Service charge to collection centres	23,27,72,845	12,64,96,115
Legal and professional charges	35,58,658	37,94,364
Cloud services and website expenses	1,09,65,114	98,29,934
Laboratory test charges	1,01,42,955	56,27,533
Payment to auditors (refer details below)	3,54,000	2,36,000
Staff hiring and training charges	64,02,139	65,96,051
Provision for Bad debts	6,60,272	-
Prior period expenses	-	28,77,025
Fixed assets written off	-	34,35,477
Miscellaneous expenses	88,80,188	1,74,85,288
	53,76,40,812	41,21,97,738

Payment to auditors

March 31, 2019

As auditor:		
Audit fees	1,77,000	1,77,000
Tax audit fees	59,000	59,000
GST audit fee	1,18,000	-
	3,54,000	2,36,000

24. Earnings per share (EPS)

Basic earnings per equity share has been computed by dividing net profit after tax by the weighted average number of equity shares outstanding for the year. Diluted earnings per equity share has been computed using the weighted average number of equity shares and dilutive potential equity shares outstanding during the year.

	March 31, 2020	March 31, 2019
Net Profit after tax	(44,23,80,087)	(46,70,01,554)
Weighted average number of equity shares outstanding during the year	1,00,00,000	1,00,00,000
Nominal value of equity share	10,00,00,000	10,00,00,000
Basic EPS per share	(44.24)	(46.70)
Diluted EPS per share	(44.24)	(46.70)

1. Basic and Diluted EPS have been calculated only considering the number of Equity shares.

2. Non-participating optionally convertible preference shares, non-participating compulsory convertible preference shares, optionally convertible debentures and compulsory convertible debentures that could potentially dilute basic earnings per share in the future have not been included in the calculation of diluted earnings per share because they are antidilutive for the year ended March 31, 2020 and March 31, 2019.



25. Employment benefits :-

(a) Defined contribution plan

The Company makes Provident Fund and Employees State Insurance Scheme contribution which are defined contribution plans. Under the scheme the company is required to contribute a specified percentage of the payroll to fund the benefits. The company has recognised Rs. 1,49,86,112/- (Previous year March 31, 2019 Rs.1,21,74,262/-) and Rs. 22,93,789/- (Previous year March 31, 2019 Rs.22,74,837/-) towards contribution to provident fund & employees state insurance scheme respectively in the profit & loss for the year ended March 31, 2020. The contribution payable to these plans by the company are at the rates specified in the rules of the scheme.

There are numerous interpretative issues relating to Hon'ble Supreme Court of India vide its judgement dated february 28, 2019 on provident fund on the inclusion of allowance for the purpose of PF contribution as well as it's applicability of effective date. Based on legal inputs received regarding various interpretative issues, the Company does not expect any liability on account of the same.

(b) Defined benefit plan

The Company has a defined benefit gratuity plan. Every employee who has completed five years or more of service gets a gratuity on departure at 15 days salary (last drawn salary) for each completed year of service or part thereof in excess of six months.

The following tables summarise the components of net benefit expense recognized in the statement of profit and loss and amounts recognized in the balance sheet for the gratuity plan.

Statement of profit and loss

Net employee benefit expense recognized in employee cost:

	March 31, 2020	March 31, 2019
Current service cost	47,62,325	32,12,196
Interest cost on benefit obligation	3,58,738	1,78,823
Net actuarial (gain) / loss recognized in the year	4,49,268	(10,00,362)
Net benefit expense	55,70,331	23,90,657

Balance Sheet

Benefit Asset / Liability

	March 31, 2020	March 31, 2019
Present value of defined benefit obligation	1,02,53,591	46,83,260
Plan (liability)	1,02,53,591	46,83,260

Change in present value of the defined benefit obligation are as follows:

	March 31, 2020	March 31, 2019
Opening defined benefit obligation	46,83,260	22,92,603
Current service cost	47,62,325	32,12,196
Interest cost	3,58,738	1,78,823
Actuarial (gain) / loss	4,49,268	(10,00,362)
Closing defined benefit obligation	1,02,53,591	46,83,260

The principal assumptions used in determining gratuity obligations for the Company's plans are shown below:

	March 31, 2020	March 31, 2019
	(%)	(%)
Discount rate	6.77	7.66
Increase in compensation cost	9.00	9.00
Employee turnover	8.00	8.00

The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.



26. Segment Information

a. Basis of Segmentation

The operation of the company are limited to one segment, viz. running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Cytology, other pathological investigations which is considered the only reportable segment as per AS-17.

b. Geographical Segment

The company operates only in one country and does not have any separate identifiable geographic segment.

c. Major customer

No single customer has accounted for more than 10% of the company's revenue for the year ended March 31, 2020.

27. Contingent Liabilities

The Company doesn't foresee any liability arising in future on account of any litigation/event not accounted for.

28. Capital & other commitments

(i) Estimated amounts of contracts remaining to be executed on capital account & not provided for is Rs.41,18,744/- (previous year Rs.38,60,548/-)

(ii) The Company has also entered into other commitments for purchase order of reagents and chemicals which are issued only after considering the requirements per operating cycle for sale of service. Such commitments have been entered in lieu of machineries costs and the values of such commitments is not quantifiable.

29. Details of dues to Micro and Small Enterprises as per Micro, Small and Medium Enterprise Development (MSMED) Act, 2006

Particulars	March 31, 2020	March 31, 2019
1. The principal amount and remaining unpaid to any supplier as at the end of accounting period.	37,66,356	42,04,328
2. Interest due thereon remaining unpaid to any supplier as at the end of accounting period.	Nil	Nil
3. The amount of interest paid by the buyer in terms of Section 16, of the Micro Small and Medium Enterprise Development Act, 2006 along with the amounts of the payment made to the supplier beyond the appointed day during each accounting period.	Nil	Nil
4. The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under Micro Small and Medium Enterprise Development Act, 2006.	Nil	Nil
5. The amount of interest accrued and remaining unpaid at the end of each accounting period; and	Nil	Nil
6. The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under Section 23 of the Micro Small and Medium Enterprise Development Act, 2006.	Nil	Nil

Note: Due to outbreak of Covid-19 in march 2020 and subsequent national lockdown imposed by the Government of India on March 24, 2020, the Company could not make timely payments to its MSME vendors. The Company has not provided for interest on such outstanding payments.

30. Assets taken on operating leases

The Company has taken the offices/labs at various locations under operating lease agreements, These are generally cancelled at the option of the company & are renewed by the mutual consent on mutually agreed terms. The lease payments recognised in the profit & loss for the year ended March 31, 2020 is Rs. 5,11,52,374/- (Previous year March 31, 2019 Rs.4,40,77,902/)

Below is the disclosure & future minimum lease payments :-

Particulars	March 31, 2020	March 31, 2019
Within one year	4,81,96,869	4,07,44,062
After one year but not more than five years	22,02,01,994	18,43,63,019
More than five years	11,75,85,994	15,01,08,398



31. Related party disclosures

List of related parties and relationships with whom transactions have taken place during the year

1. List of related parties

Key Management Personnel (KMP)

Mr. Rajeev Juneja
Mr. Arjun Juneja
Mr. Sheetal Arora
Mr. Sanjeev Vashishta
Mr. Eklavya Juneja
Mr. Surendra Lunia

Enterprises on which KMP exercise significant influence

Mankind Pharma Limited
Mankind Biosys Private Limited
Beyondtime Consultants Private Limited
A S Packers
J K Print Pack
Mankind Specialities
N S Industries
Pharma Force Lab
Paonta Process Equipment
Copmed Pharmaceuticals Private Limited
Mediforce Healthcare Private Limited
Sirmour Remedies Private Limited
Relax Pharmaceuticals Private Limited
Vetbesta Labs
Medipack Innovations Private Limited
Pharma Pet
A To Z Packers
Star Infra P Ltd
Juneja Hospital Paonta Sahib



Pathkind Diagnostics Private Limited
Notes to financial statements for the year ended March 31, 2020
All amounts are in INR unless otherwise stated

ii. Transactions occurred during the year

Particulars	KMP		Enterprises over which KMP exercise significant influence	
	March 31, 2020	March 31, 2019	March 31, 2020	March 31, 2019
A. Sale of services				
Mankind Pharma Limited	-	-	7,52,400	4,88,000
A S Packers	-	-	6,050	4,500
J K Print Pack	-	-	1,18,800	1,23,500
Mankind Specialities	-	-	11,000	12,500
N S Industries	-	-	2,200	2,500
Pharma Force Lab	-	-	1,80,400	1,53,000
Paonta Process Equipment	-	-	3,300	2,000
Copmed Pharmaceuticals Private Limited	-	-	1,54,000	1,43,500
Mediforce Healthcare Private Limited	-	-	1,30,900	1,09,500
Sirmour Remedies Private Limited	-	-	93,500	76,000
Relax Pharmaceuticals Private Limited	-	-	1,03,400	98,000
Vetbesta Labs	-	-	31,900	31,000
Medipack Innovations Private Limited	-	-	52,250	40,500
Pharma Pet	-	-	-	8,000
A To Z Packers	-	-	37,400	40,500
Juneja Hospital Paonta Sahib	-	-	12,24,675	-
			29,02,175	13,33,000
B. Purchase of goods (net)				
Mankind Pharma Limited	-	-	20,896	1,54,759
A S Packers	-	-	15,49,91,334	1,16,81,118
A To Z Packers	-	-	3,25,668	-
			15,53,37,898	1,18,35,877
C. Purchase of services				
Mankind Pharma Limited	-	-	-	59,966
Star Infra Developers Pvt. Ltd.	-	-	2,06,661	-
			2,06,661	59,966
D. Rent expense				
Mankind Pharma Limited	-	-	-	96,32,449
Mankind Biosys Private Limited	-	-	1,95,61,272	97,80,636
			1,95,61,272	1,94,13,085
F. Reimbursements made				
Mankind Biosys Private Limited	-	-	43,81,855	9,01,685
Mr. Sanjeev Vashishta	8,12,858.00	10,27,343	-	-
Mr. Eklavaya Juneja	3,38,636.00	52,072	-	-
	11,51,494	10,79,415	43,81,855	9,01,685
F. Security deposits paid				
Mankind Biosys Private Limited	-	-	-	82,88,676
				82,88,676
G. Remuneration paid				
Mr. Sanjeev Vashishta	3,10,70,000	3,12,36,667	-	-
	3,10,70,000	3,12,36,667	-	-
H. Issue of debentures (includes securities premium)				
(2,42,91,800 0.1% Compulsory Convertible Debentures (previous year 2,30,00,000 0.1% Compulsory Convertible Debentures)				
Mr. Arjun Juneja	6,07,29,500	5,75,00,000	-	-
Mr. Rajeev Juneja	11,41,71,460	10,81,00,000	-	-
Mr. Sheetal Arora	6,80,17,040	6,44,00,000	-	-
	24,29,18,000	23,00,00,000	-	-



Pathkind Diagnostics Private Limited
Notes to financial statements for the year ended March 31, 2019
All amounts are in INR unless otherwise stated

III. Balances outstanding as at the year end

Particulars	KMP		Enterprises over which KMP exercise significant influence	
	As at March 31, 2020	As at March 31, 2019	As at March 31, 2020	As at March 31, 2019
A. Trade receivables				
Mankind Pharma Limited	-	-	-	4,000
J.K Print Pack	-	-	1,06,920	-
N.S. Industries	-	-	2,200	100
Pharma Force Lab	-	-	2,970	-
Copmed Pharmaceuticals Private Limited	-	-	86,130	2,550
Mediforce Healthcare Private Limited	-	-	-	12,825
Juneja Hospital Paonta Sahib	-	-	1,11,445	-
			3,09,665	19,475
B. Trade payables				
Mankind Pharma Ltd	-	-	4,65,982	-
A. S. Packers	-	-	14,10,348	18,41,477
			18,76,330	18,41,477
D. Loans and advances to related parties include				
Mr. Sanjeev Vashishta	3,00,00,000	3,00,00,000	-	-
	3,00,00,000	3,00,00,000	-	-
E. 0.1% Optionally Convertible Debentures				
Beyondtime Consultants Private Limited	-	-	2,50,00,000	2,50,00,000
	-	-	2,50,00,000	2,50,00,000
F. 0.1% Compulsory Convertible Debentures (Includes securities premium)				
Mr. Arjun Juneja	21,17,79,500	15,10,50,000	-	-
Mr. Rajeev Juneja	31,95,21,460	20,53,50,000	-	-
Mr. Sheetal Arora	20,66,17,040	13,86,00,000	-	-
	73,79,18,000	49,50,00,000	-	-



Pathkind Diagnostics Private Limited
Notes to financial statements for the year ended March 31, 2020
All amounts are in INR unless otherwise stated

32. Disclosure pursuant to AS-5 "Net Profit or Loss for the Period, Prior Period Items and Changes in Accounting Policies" (specified under section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2015 are given below: Following are the restatements made in the current year financial statements related to previous year.

Particulars	Reported	Restated	Nature
For the year ended on March 31, 2019			
Revenue from operations	31,46,14,077	42,47,78,606	Adjustment of AS-5
Service charges to collection centres	1,63,31,586	12,64,96,115	Adjustment of AS-5

The above restatements in previous year has been made because of the change in accounting policy as disclosed in Note 2.3. The company has applied retrospective approach in adopting the change in accounting policy and accordingly has given cumulative effect of applying this standard on the opening balance of retained earnings as at April 01, 2018 by Nil and restated the figures of March 31, 2019 as disclosed above. These restatements have no impact on the previous year profit / (loss).

33. There were no amounts which were required to be transferred to Investors Education and Protection Fund.


34. The spread of Covid-19 from Last week of March is having an unprecedented impact on people and economy. However, there is no significant impact on company's operations and results for the year ended March 31, 2020, due to this short duration during this Financial Year.


The Company has considered all possible effects that may result from the pandemic relating to COVID-19 on the carrying amounts of trade receivables, tangible assets, intangible assets, assets under strategic review and investments. In developing the assumptions relating to the possible future uncertainties in the economic conditions because of this pandemic, the Company, as at the date of approval of these financial statements has used internal and external sources of information. The Company based on current estimates expects the carrying amount of these assets will be recovered.

35. Previous year figures have been regrouped/ rearranged wherever necessary to conform to current year's classification.

For and on behalf of the Board of Directors


Eklavya Juneja
 (Director)
 DIN:-06754247


Sanjeev Vashistha
 (Managing Director & CEO)
 DIN:-01457971


Prabhat Singh
 (Company Secretary)
 M. No:- FCS-8724



Place:
 Date: 08-12-2020